Triangle Securities Wealth Management Reduces Position in Becton, Dickinson and Company $BDX

Key Points

• Triangle Securities Wealth Management has reduced its position in Becton, Dickinson and Company by 45.4%, leaving it with a stock worth approximately $752,000 after selling over 3,600 shares in the last quarter.
• Institutional investors control 86.97% of Becton, Dickinson and Company's stock, indicating significant institutional interest, with several firms establishing new positions recently.
• Analysts have mixed reviews on the stock, with a consensus target price of $213.30, as some upgraded their ratings while others reduced their target prices amidst changing market conditions.

Triangle Securities Wealth Management cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 45.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,363 shares of the medical instruments supplier's stock after selling 3,632 shares during the quarter. Triangle Securities Wealth Management's holdings in Becton, Dickinson and Company were worth $752,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BDX. Brighton Jones LLC boosted its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares during the last quarter. FORA Capital LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter worth $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth about $6,406,000. Finally, GAMMA Investing LLC grew its position in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after acquiring an additional 748 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock traded down $1.10 during trading on Friday, reaching $187.27. The company's stock had a trading volume of 2,750,943 shares, compared to its average volume of 1,535,837. The business's 50-day moving average price is $187.65 and its 200-day moving average price is $190.16. The firm has a market cap of $53.68 billion, a PE ratio of 33.68, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 earnings per share. The business's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 over the last 90 days. 0.36% of the stock is owned by company insiders.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reissued a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Barclays cut their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $213.30.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.